Zoetis Expands Precision Animal Health with $160M Neogen Genomics Buy
Event summary
- Zoetis to acquire Neogen’s animal genomics business for $160M, subject to closing adjustments.
- Deal includes five labs across the U.S., Brazil, Australia, China, and the U.K., plus a Canadian office.
- Neogen’s genomics business is a leader in U.S. beef and dairy genomics, with a global customer base.
- Transaction expected to close in the second half of 2026, pending regulatory approvals.
- Acquisition strengthens Zoetis’ Precision Animal Health portfolio with predictive insights and individualized care.
The big picture
Zoetis’ acquisition of Neogen’s genomics business underscores the growing importance of data-driven precision animal health. The deal aligns with broader industry trends toward leveraging genomic insights for predictive care, particularly in livestock. With a $160M price tag, the acquisition signals Zoetis’ commitment to expanding its global footprint and reinforcing its leadership in animal health innovation.
What we're watching
- Integration Challenges
- How Zoetis will merge Neogen’s genomic technologies into its existing Precision Animal Health portfolio.
- Regulatory Approvals
- Whether the deal will face regulatory hurdles and the timeline for closing in the second half of 2026.
- Market Impact
- The pace at which Zoetis can leverage Neogen’s genomic data to drive innovation in livestock and companion animal health.
Related topics